Liver Cancer: Efficacy and safety of Cabozantinib in the treatment of advanced liver cancer: from an international multi-center real world study

Hepatocellular carcinoma (HCC) is a common malignant tumor.

Hepatocellular carcinoma (HCC) is a common malignant tumor.

The study retrospectively included patients with advanced liver cancer from 11 research centers in Australia, Switzerland, and Germany, and collected the clinical characteristics, treatment adverse events, treatment duration and overall survival (OS) of the patients.

The study retrospectively included patients with advanced liver cancer from 11 research centers in Australia, Switzerland, and Germany, and collected the clinical characteristics, treatment adverse events, treatment duration and overall survival (OS) of the patients.

81 patients (92%) had received sorafenib before treatment with cabozantinib.

Efficacy evaluation showed that 6 patients (7%) achieved partial remission (PR), 28 patients (32%) reached stable, and 28 patients (32%) developed disease progression (PD).

Cabozantinib in the treatment of OS and PFS in the general population

For patients with PR and stability, the median OS was 423 days, while the median OS for PD patients was 187 days (HR=2.

For patients with PR and stability, the median OS was 423 days, while the median OS for PD patients was 187 days (HR=2.

OS in patients responding to different treatments

The median OS of Child-Pugh A patients was 9.

The median OS of Child-Pugh A patients was 9.

OS in Child-Pugh A and B patients

Forty-five patients (51%) reported at least one adverse event (AE).

Forty-five patients (51%) reported at least one adverse event (AE).

Treatment of common adverse reactions

In summary, Cabozantinib is an effective, safe and feasible measure for the treatment of advanced liver cancer.

In summary, Cabozantinib is an effective, safe and feasible measure for the treatment of advanced liver cancer.
Cabozantinib is an effective, safe and feasible measure for the treatment of advanced liver cancer.
Cabozantinib is an effective, safe and feasible measure for the treatment of advanced liver cancer.

Original source:

Original source:

Fabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.
Liver Cancer.
2021.
DOI: 10.
1159/000515490.
Published online: June 1, 2021.

Fabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.
Liver Cancer.
2021.
DOI: 10.
1159/000515490.
Published online: June 1, 2021.


Leave a message here